- Title
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- Creator
- Hughes, Timothy P.; Branford, Susan; Cooney, Julian; Leahy, Michael F.; Rowlings, Philip; Catalano, John; Hertzberg, Mark; Filshie, Robin; Mills, Anthony K.; Fay, Keith; Durrant, Simon; Januszewicz, Henry; White, Deborah L.; Joske, David; Underhill, Craig; Dunkley, Scott; Lynch, Kevin; Grigg, Andrew; Reynolds, John; Koelmeyer, Rachel; Seymour, John F.; Taylor, Kerry; Arthur, Chris; Schwarer, Anthony K.; Morton, James
- Relation
- Blood Vol. 112, Issue 10, p. 3965-3973
- Publisher Link
- http://dx.doi.org/10.1182/blood-2008-06-161737
- Publisher
- American Society of Hematology
- Resource Type
- journal article
- Date
- 2008
- Description
- We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for suboptimal response. The estimated cumulative incidences of complete cytogenetic response (CCR) by 12 and 24 months were 88% and 90%, and major molecular responses (MMRs) were 47% and 73%. In patients who maintained a daily average of 600 mg of imatinib for the first 6 months (n = 60), MMR rates by 12 and 24 months were 55% and 77% compared with 32% and 53% in patients averaging less than 600 mg (P = .037 and .016, respectively). Dose escalation was indicated for 17 patients before 12 months for failure to achieve, or maintain, major cytogenetic response at 6 months or CCR at 9 months but was only possible in 8 patients (47%). Dose escalation was indicated for 73 patients after 12 months because their BCR-ABL level remained more than 0.01% (international scale) and was possible in 45 of 73 (62%). Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimize response in CP-CML. The trial was registered at www.ANZCTR.org.au as #ACTRN12607000614493.
- Subject
- chronic phase chronic myeloid leukemia (CP-CML); imatinib mesylate; cytogenetic response; dose intensity
- Identifier
- http://hdl.handle.net/1959.13/42906
- Identifier
- uon:5045
- Identifier
- ISSN:0006-4971
- Language
- eng
- Reviewed
- Hits: 34920
- Visitors: 35485
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|